Literature DB >> 35289055

2022 Alzheimer's disease facts and figures.

.   

Abstract

This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report discusses consumers' and primary care physicians' perspectives on awareness, diagnosis and treatment of mild cognitive impairment (MCI), including MCI due to Alzheimer's disease. An estimated 6.5 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available. Alzheimer's disease was officially listed as the sixth-leading cause of death in the United States in 2019 and the seventh-leading cause of death in 2020 and 2021, when COVID-19 entered the ranks of the top ten causes of death. Alzheimer's remains the fifth-leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. More than 11 million family members and other unpaid caregivers provided an estimated 16 billion hours of care to people with Alzheimer's or other dementias in 2021. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $271.6 billion in 2021. Its costs, however, extend to family caregivers' increased risk for emotional distress and negative mental and physical health outcomes - costs that have been aggravated by COVID-19. Members of the dementia care workforce have also been affected by COVID-19. As essential care workers, some have opted to change jobs to protect their own health and the health of their families. However, this occurs at a time when more members of the dementia care workforce are needed. Average per-person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are almost three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 22 times as great. Total payments in 2022 for health care, long-term care and hospice services for people age 65 and older with dementia are estimated to be $321 billion. A recent survey commissioned by the Alzheimer's Association revealed several barriers to consumers' understanding of MCI. The survey showed low awareness of MCI among Americans, a reluctance among Americans to see their doctor after noticing MCI symptoms, and persistent challenges for primary care physicians in diagnosing MCI. Survey results indicate the need to improve MCI awareness and diagnosis, especially in underserved communities, and to encourage greater participation in MCI-related clinical trials.
© 2022 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's dementia; Alzheimer's disease; Biomarkers; COVID-19; Caregivers; Dementia; Dementia workforce; Diagnostic criteria; Family caregiver; Health care costs; Health care expenditures; Health care professional; Incidence; Long-term care costs; MCI due to Alzheimer's disease; Medicaid spending; Medicare spending; Mild cognitive impairment; Morbidity; Mortality; Prevalence; Primary care physician; Risk factors; Spouse caregiver

Mesh:

Year:  2022        PMID: 35289055     DOI: 10.1002/alz.12638

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  53 in total

Review 1.  Autophagy in health and disease: From molecular mechanisms to therapeutic target.

Authors:  Guang Lu; Yu Wang; Yin Shi; Zhe Zhang; Canhua Huang; Weifeng He; Chuang Wang; Han-Ming Shen
Journal:  MedComm (2020)       Date:  2022-07-10

Review 2.  Neuropathologic Changes Provide Insights into Key Mechanisms of Alzheimer Disease and Related Dementia.

Authors:  Germán Plascencia-Villa; George Perry
Journal:  Am J Pathol       Date:  2022-08-02       Impact factor: 5.770

3.  Development and External Validation of a Mortality Prediction Model for Community-Dwelling Older Adults With Dementia.

Authors:  W James Deardorff; Deborah E Barnes; Sun Y Jeon; W John Boscardin; Kenneth M Langa; Kenneth E Covinsky; Susan L Mitchell; Elizabeth L Whitlock; Alexander K Smith; Sei J Lee
Journal:  JAMA Intern Med       Date:  2022-09-26       Impact factor: 44.409

4.  BAY 11-7082 inhibits the secretion of interleukin-6 by senescent human microglia.

Authors:  Maxwell Cook; Houmin Lin; Sandeep K Mishra; Gavin Y Wang
Journal:  Biochem Biophys Res Commun       Date:  2022-05-30       Impact factor: 3.322

Review 5.  How neurons die in Alzheimer's disease: Implications for neuroinflammation.

Authors:  Aman Mangalmurti; John R Lukens
Journal:  Curr Opin Neurobiol       Date:  2022-06-10       Impact factor: 7.070

6.  Engaging and Supporting Care Partners of Persons With Dementia in Health-Care Delivery: Results From a National Consensus Conference.

Authors:  Catherine Riffin; Joan M Griffin; Lilla Brody; Jennifer L Wolff; Karl A Pillemer; Ronald D Adelman; Lauren R Bangerter; Steven M Starks; Francesca Falzarano; Martha Villanigro-Santiago; Loretta Veney; Sara J Czaja
Journal:  Public Policy Aging Rep       Date:  2022-04-25

7.  A Randomized Controlled Trial Study of a Multimodal Intervention vs. Cognitive Training to Foster Cognitive and Affective Health in Older Adults.

Authors:  Maria Brasser; Sascha Frühholz; Andres R Schneeberger; Gian G Ruschetti; Rahel Schaerli; Michèle Häner; Barbara Studer-Luethi
Journal:  Front Psychol       Date:  2022-06-20

8.  A Diagnostic Model for Alzheimer's Disease Based on Blood Levels of Autophagy-Related Genes.

Authors:  Qiangqiang Qin; Zhanfeng Gu; Fei Li; Yanbing Pan; TianXiang Zhang; Yang Fang; Lesha Zhang
Journal:  Front Aging Neurosci       Date:  2022-05-12       Impact factor: 5.702

9.  Design, Synthesis, and In Vitro, In Silico and In Cellulo Evaluation of New Pyrimidine and Pyridine Amide and Carbamate Derivatives as Multi-Functional Cholinesterase Inhibitors.

Authors:  Martina Bortolami; Fabiana Pandolfi; Valeria Tudino; Antonella Messore; Valentina Noemi Madia; Daniela De Vita; Roberto Di Santo; Roberta Costi; Isabella Romeo; Stefano Alcaro; Marisa Colone; Annarita Stringaro; Alba Espargaró; Raimon Sabatè; Luigi Scipione
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

Review 10.  Insights Into the Role of Mortalin in Alzheimer's Disease, Parkinson's Disease, and HIV-1-Associated Neurocognitive Disorders.

Authors:  Pankaj Seth
Journal:  Front Cell Dev Biol       Date:  2022-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.